Introduction {#section6-1178224218823509}
============

Advance care planning is the process of determining future health care needs for a time when a person may be unable to speak for themselves due to illness or impaired cognition.^[@bibr1-1178224218823509],[@bibr2-1178224218823509]^ It involves multiple steps: discussing options for future care, appointing a substitute decision maker, discussing care options, priorities and preferences, and documenting those preferences for future consideration.^[@bibr1-1178224218823509]^ It can be a complex process that may need to take place over time.^[@bibr3-1178224218823509]^

An advance care plan that balances clinical realities with patients' values and priorities^[@bibr1-1178224218823509]^ may reduce unwanted, burdensome or intensive treatments at the end-of-life in line with patients' care preferences.^[@bibr4-1178224218823509],[@bibr5-1178224218823509]^ It may give greater control over psychological and physical symptoms^[@bibr3-1178224218823509][@bibr4-1178224218823509]--[@bibr5-1178224218823509]^ and reduce stress, anxiety and depression in surviving relatives.^[@bibr1-1178224218823509],[@bibr6-1178224218823509],[@bibr7-1178224218823509]^ There is also the potential to reduce health care spending at the end-of-life on resource-intensive, inappropriate or futile interventions that may contribute to increased suffering for patients, their families and carers.^[@bibr7-1178224218823509],[@bibr8-1178224218823509]^ It may also facilitate better access to palliative care or hospice services.^[@bibr3-1178224218823509],[@bibr9-1178224218823509]^

Rapid Response Systems have been established in many hospitals in Australia and internationally^[@bibr10-1178224218823509],[@bibr11-1178224218823509]^ to provide a prompt response to critical patients to prevent further deterioration, unexpected deaths, cardiac arrest or the need to transfer patients to an Intensive Care Unit (ICU).^[@bibr12-1178224218823509],[@bibr13-1178224218823509]^ Staff activate a Rapid Response Team (RRT) review according to established criteria which may indicate physiological instability,^[@bibr12-1178224218823509],[@bibr14-1178224218823509]^ or concern about a patient's condition. A person in the process of dying can also trigger activation due to meeting one or more of the calling criteria.^[@bibr15-1178224218823509]^ Over time, the RRT has taken on secondary functions: the diagnosis of dying, initiating end-of-life discussions and establishing limitations of medical treatment.^[@bibr13-1178224218823509],[@bibr15-1178224218823509][@bibr16-1178224218823509][@bibr17-1178224218823509][@bibr18-1178224218823509][@bibr19-1178224218823509]--[@bibr20-1178224218823509]^ However, the RRT may not always adequately address the needs of patients at the end-of-life due to limited access to comprehensive information about current illness, disease trajectory, and treatment and care preferences. This may be better addressed as part of an advance care planning process.^[@bibr21-1178224218823509]^

A systematic review of the role of the RRT in end-of-life care by Jones and colleagues^[@bibr15-1178224218823509]^ reported up to one-third of RRT reviews may involve a patient approaching the end-of-life. These teams had a role in establishing limitations of medical treatment or not for resuscitation orders, conducting patient and family meetings, documentation of comfort care orders and initiating chaplain visits. Similarly, Tan and Delaney^[@bibr22-1178224218823509]^ found the RRT had a vital role in providing end-of-life interventions which included establishing limitations of medical treatment. These reviews provide a greater understanding of the role of the RRT with patients at the end-of-life.

Little is known about the influence of RRT reviews on the broader provision of advance care planning that integrates patient values, preferences and priorities. This includes the prevalence of pre-existing written advance directives, and whether the RRT review prompts discussing and documenting care preferences and priorities and establishing a legal substitute decision maker. This represents a current gap in the literature. Further understanding of how advance care planning may impact the care provided at the time of a clinical deterioration in hospital is needed. With up to one-third of patients requiring RRT review approaching the end-of-life, this is a critical event that should prompt health professionals to initiate an advance care planning discussion for many patients.

Aim {#section7-1178224218823509}
===

In response to the aforementioned knowledge and practice gaps, this systematic review aims to examine the current research evidence by considering observational and experimental studies that can contribute further knowledge of the provision of advance care planning. This is in relation to the clinical deterioration of patients in hospital requiring RRT review. It examines trends in discussions between medical teams and patients, families or substitute decision makers and how formal, pre-existing advance directives are documented and influence care planning. Prompts for further establishment of patient goals, priorities and preferences for medical care and treatment, and referral for specialist palliative care management is examined.

Method {#section8-1178224218823509}
======

This systematic literature review was conducted using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) approach.^[@bibr23-1178224218823509]^

Eligibility criteria {#section9-1178224218823509}
--------------------

A systematic search was conducted to identify studies that described the deployment of an RRT, related to end-of-life decision making with human participants, described aspects of advance care planning and described an experimental or observational study. Studies addressing paediatric or mental health RRT calls were not within the scope of this study as the focus was on patients who are likely to benefit from the provision of advance care planning due to their current medical condition or illness trajectory with a particular focus on end-of-life care. Papers not published in English were also excluded if no translation was readily available. There is debate as to whether the establishment of Not for Resuscitation and Limitations of Medical Treatment orders form part of the advance care planning process.^[@bibr21-1178224218823509]^ For the purposes of this review, articles that only focussed on these medical orders without reporting on broader aspects of advance care planning were excluded.

Search {#section10-1178224218823509}
------

An electronic Title/Abstract/Keyword search of relevant literature was performed using Scopus®, PubMed and PsycNet. Search terms were Medical Subject Heading (MeSH) keyword searches for 'Advance Care Planning', 'Advance Directive', AND 'Hospital Rapid Response Team' and METeOR term 'Rapid Response Team'. Searches were performed to identify peer-reviewed manuscripts up to August 2017. Searches of reference lists in published manuscripts were also conducted to ensure other relevant studies were captured.

Study selection {#section11-1178224218823509}
---------------

Articles returned from the electronic database searches were imported into Endnote (version X7), and the titles and abstracts of all papers were examined by the first author to ascertain whether they met the inclusion criteria.

Data collection and items {#section12-1178224218823509}
-------------------------

Data were compiled into table format in Microsoft Word. Items included the publication year; hospital type; bed numbers; country; study design; main findings ([Table 1](#table1-1178224218823509){ref-type="table"}); total patient numbers; total RRT reviews; not for resuscitation and limitations of medical treatment before and after clinical deterioration requiring RRT review; pre-existing advance care planning documents; discussions with the patient, family or proxy decision maker; palliative care consultation; escalation to higher level care; and in-hospital mortality ([Table 2](#table2-1178224218823509){ref-type="table"}). Numbers were expressed as a percentage of RRT reviews or number of patients where RRT review figures was not available.

###### 

Study type, methods and main findings.

![](10.1177_1178224218823509-table1)

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study first author                                                                  Year   Hospital type (beds)                                 Country                 Study design                                           Main findings
  ----------------------------------------------------------------------------------- ------ ---------------------------------------------------- ----------------------- ------------------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Austin^[@bibr24-1178224218823509]^                                                  2014   Academic (800+) with specialist cancer centre (50)   The United States       Retrospective cohort                                   NFR orders created before, during and after the RRT review were low, at 9.6%, 3% and 13.3%, respectively. RRT activations were higher for oncology patients than general medical patients (37.34 v 20.86 per 1000 patient discharges)

  Boniatti^[@bibr25-1178224218823509]^                                                2010   Academic (794)                                       Brazil                  Retrospective observational                            RRT review is associated with a high 30-day mortality, with NFR orders before and after the RRT review 5.1% and 3.3%, respectively

  Calzavacca^[@bibr26-1178224218823509]^                                              2010   Tertiary (400)                                       Australia               Retrospective observational                            22.7% of patients had an NFR order prior to RRT review and an additional 8.5% after. Patients with multiple RRT reviews have increased risk of mortality

  Calzavacca^[@bibr27-1178224218823509]^                                              2010   Tertiary (400)                                       Australia               Retrospective observational                            15% of patients had an NFR order prior to RRT review and further 9.5% after

  Calzavacca^[@bibr28-1178224218823509]^                                              2008   Tertiary (NS)                                        Australia               Prospective observational                              Presence of NFR orders was independently associated with mortality

  Cardona-Morrell^[@bibr29-1178224218823509]^                                         2016   Teaching (NS)                                        Australia               Retrospective case-control analysis                    Older patients requiring RRT with pre-existing LOMT or multiple indicators of chronic illness, cognitive impairment and frailty had a higher risk of death

  Casamento^[@bibr30-1178224218823509]^                                               2008   General (NS)                                         Australia               Prospective audit and chart review                     High in-hospital mortality following RRT review (32%)

  Chen^[@bibr20-1178224218823509]^                                                    2008   23 hospitals                                         Australia               Cluster randomized control trial                       NFR orders were uncommon for people receiving RRT review for cardiac arrest or unplanned ICU admission, due to limited time in which to discuss end-of-life wishes

  Dargin^[@bibr31-1178224218823509]^                                                  2014   Tertiary (350)                                       The United States       Retrospective                                          High in-hospital mortality for patients following RRT review. End-of-life care may be improved with better coordination between medical teams and palliative care

  Downar^[@bibr32-1178224218823509]^                                                  2013   3 academic (NS)                                      Canada                  Retrospective                                          In-hospital mortality for patients with an NFR order was high. RRTs frequently facilitate end-of-life discussions and decision making

  Gouda and Alqahtani^[@bibr33-1178224218823509]^                                     2016   Tertiary (1200)                                      Saudi Arabia            Retrospective chart review                             RRTs have a key role in addressing and initiating NFR orders

  Jäderling^[@bibr34-1178224218823509]^                                               2013   Teaching (650)                                       Sweden                  Observational cohort                                   In-hospital mortality for patients with NFR orders was high in the short- and long-term. Decisions about limitations of treatment are often made close to the time of the RRT review and did not preclude further RRT reviews

  Jäderling^[@bibr35-1178224218823509]^                                               2011   2 Teaching (650)/(400)                               Sweden\                 Two-centre prospective observational study             Similarities in pre-existing LOMT (34.2% and 30.8%) and those implemented after RRT review (14.4% and 12.6%) were found between two different centres in Sweden and Australia, respectively
                                                                                                                                                  Australia                                                                      

  Jones^[@bibr11-1178224218823509]^                                                   2012   7 Academic                                           Australia (5)\          Prospective audit                                      Approximately one-third of RRT reviews involved end-of-life and LOMT issues, highlighting a need for improved advance care planning
                                                                                                                                                  Canada (1) Sweden (1)                                                          

  Medical Emergency Team End-of-Life Care investigators^[@bibr14-1178224218823509]^   2013   7 Academic                                           Australia (5)\          Prospective audit                                      Patients who required RRT review later in the admission (after day 7) were more likely to have a LOMT than patients receiving review on day 0 or 1
                                                                                                                                                  Canada (1) Sweden (1)                                                          

  Knott^[@bibr17-1178224218823509]^                                                   2011   Tertiary teaching (450)                              New Zealand             Retrospective cohort                                   LOMT and NFR documentation rates doubled after RRT review

  O'Horo^[@bibr36-1178224218823509]^                                                  2015   Tertiary (NS)                                        The United States       Retrospective chart review and prospective survey      Involvement of the primary treating team in RRT reviews was associated with significantly higher transfers to higher level care and discussion about code status

  Parr^[@bibr37-1178224218823509]^                                                    2001   Tertiary (580)                                       Australia               Retrospective cohort                                   The RRT can identify patient for whom an NFR should be considered

  Psirides^[@bibr38-1178224218823509]^                                                2016   11 (including 6 tertiary, 1 paediatric)              New Zealand             Prospective multicentre observational                  RRT reviews resulted in new NFR orders (22.5%), altered early warning system calling criteria (10.8%) and other treatment limitations (8.8%)

  Schneider^[@bibr39-1178224218823509]^                                               2011   Teaching (400)                                       Australia               Retrospective cohort                                   Atrial fibrillation was a trigger for approximately 10% of RRT activations

  Silva^[@bibr40-1178224218823509]^                                                   2016   Tertiary academic (600)                              Portugal                Retrospective cohort                                   Prior to RRT activation, 5.1% of patients had an NFR order and 2.5% had a withhold therapy decision. An additional 24.1% had end-of-life decisions as part of the RRT actions

  Smith^[@bibr41-1178224218823509]^                                                   2014   Tertiary (300)                                       The United States       Retrospective audit (non-cardiac arrest events only)   NFR orders were in place before the RRT review for 11.01% of patients, with an additional 5.5% created at the time of the RRT review

  Smith^[@bibr42-1178224218823509]^                                                   2015   Academic teaching (400)                              Australia               Retrospective cohort                                   NFR implemented by RRT during early reviews (\<48 h of admission) in 3.91% of cases, 5.45% for intermediate cases (48\<168 h after admission) and 8.39% in late cases (⩾168 h after admission)

  Smith^[@bibr13-1178224218823509]^                                                   2014   Tertiary (NS)                                        Australia               Retrospective, quasi-experimental                      28% of RRT reviews were associated with an NFR order. In 11.5% of instances, NFR was placed prior to the review

  Stelfox^[@bibr21-1178224218823509]^                                                 2015   2 tertiary, 2 community (2883)                       Canada                  Retrospective database review                          2% of patients \<50 years and 15% of patients \>80 years had goals of care changed to exclude resuscitation following RRT review

  Sulistio^[@bibr19-1178224218823509]^                                                2015   3 hospitals (NS)                                     Australia               Retrospective cohort                                   36.2% of patients had documented LOMT, 77.2% of these were instituted following the RRT review. Goals were changed to a more palliative intent in 28.5% of patients following RRT review

  Sundararajan^[@bibr43-1178224218823509]^                                            2014   Tertiary (650)                                       Australia               Prospective study                                      Pre-existing LOMT orders were more likely to have been made in consultation with the patient or NOK (patient 50%, NOK 90%) compared with LOMT associated with an RRT review (patient 18%, NOK 58%)

  Tam^[@bibr44-1178224218823509]^                                                     2014   Tertiary (458)                                       Canada                  Retrospective chart review                             6% of patients had their resuscitation status initiated or revisited by the RRT. Of these, 27% of patients had their status changed to NFR following the consultation

  Tirkkonen^[@bibr45-1178224218823509]^                                               2016   University (NS)                                      Finland                 Prospective observational                              New LOMT were issued for 9.2% patients following RRT review following discussion with the patient in 19% or cases and discussion with relatives in 69% of cases

  Tirkkonen^[@bibr46-1178224218823509]^                                               2013   Tertiary (769)                                       Finland                 Prospective observational                              NFR orders were associated with increased hospital mortality

  Visser^[@bibr47-1178224218823509]^                                                  2014   Sub-acute (NS)                                       Australia               Retrospective observational                            LOMT were documented for 79.4% patients on admission. For 22.7% of the RRT reviews, there was an increase in LOMT following review by the RRT

  White^[@bibr48-1178224218823509]^                                                   2016   University teaching (780)                            Australia               Prospective cohort                                     Few RRT activations were associated with a resuscitation order, with high mortality and transfers to ICU following RRT reviews
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

LOMT, limitations of medical treatment; NFR, not for resuscitation; NOK, next of kin; RRT, Rapid Response Team.

###### 

Care and treatment planning characteristics.

![](10.1177_1178224218823509-table2)

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study first author                                                                  Total patient numbers   Total RRT reviews                                              NFR/LOMT before RRT review                                   NFR/LOMT during or after RRT review                                  Escalation to higher level care, e.g. ICU   In-hospital mortality                       Formal advance care planning   Discussion with patient, family or proxy decision maker      Palliative care consultation
  ----------------------------------------------------------------------------------- ----------------------- -------------------------------------------------------------- ------------------------------------------------------------ -------------------------------------------------------------------- ------------------------------------------- ------------------------------------------- ------------------------------ ------------------------------------------------------------ ----------------------------------------------------------------------------
  Austin^[@bibr24-1178224218823509]^                                                  Ca centre: 135\         NS                                                             9.6%[\*](#table-fn3-1178224218823509){ref-type="table-fn"}   1.5% D[\*](#table-fn3-1178224218823509){ref-type="table-fn"}\        34.8%                                       21.5%                                       NS                             NS                                                           1.5% B[\*](#table-fn3-1178224218823509){ref-type="table-fn"}\
                                                                                      Gen med: 422\                                                                                                                                       13.3% A[\*](#table-fn3-1178224218823509){ref-type="table-fn"}                                                                                                                                                                                            4.4% A[\*](#table-fn3-1178224218823509){ref-type="table-fn"}
                                                                                      Total: 557                                                                                                                                                                                                                                                                                                                                                                                                   

  Boniatti^[@bibr25-1178224218823509]^                                                901                     1051                                                           5.1%                                                         3.3% A                                                               55.4%                                       46.9% at 30 days                            NS                             NS                                                           NS

  Calzavacca^[@bibr26-1178224218823509]^                                              1664                    2237                                                           22.7%                                                        8.5% A                                                               16%                                         34.3%                                       NS                             NS                                                           NS

  Calzavacca^[@bibr27-1178224218823509]^                                              200                     200                                                            15%                                                          9.5%                                                                 17.5%                                       27%                                         NS                             NS                                                           NS

  Calzavacca^[@bibr28-1178224218823509]^                                              228                     251                                                            14.5%                                                        9.2%                                                                 16.7%                                       40%                                         NS                             NS                                                           NS

  Cardona-Morrell^[@bibr29-1178224218823509]^                                         2353                    328^[\#](#table-fn4-1178224218823509){ref-type="table-fn"}^    12.5%                                                        32.5% D                                                              NS                                          7.8% of patients aged 60+                   5%                             NS                                                           NS

  Casamento^[@bibr30-1178224218823509]^                                               NS                      195                                                            20%                                                          15%                                                                  28%                                         34%                                         NS                             NS                                                           NS

  Chen^[@bibr20-1178224218823509]^                                                    NS                      4161^[\^](#table-fn5-1178224218823509){ref-type="table-fn"}^   45.4%                                                        3.85%                                                                19.1%                                       47.2%                                       NS                             NS                                                           NS

  Dargin^[@bibr31-1178224218823509]^                                                  998                     1156                                                           8.65%                                                        5% D                                                                 39.7%                                       17%                                         NS                             44%^[@](#table-fn6-1178224218823509){ref-type="table-fn"}^   2.68%

  Downar^[@bibr32-1178224218823509]^                                                  NS                      291                                                            8.9%                                                         NS                                                                   33%                                         24.7%                                       NS                             16.5% within 48 h                                            0% B\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   13% within 48 h^[\^\^](#table-fn7-1178224218823509){ref-type="table-fn"}^\
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   17% after 48 h^[\^\^](#table-fn7-1178224218823509){ref-type="table-fn"}^

  Gouda and Alqahtani^[@bibr33-1178224218823509]^                                     NS                      5904                                                                                                                        6.66% D\                                                             34.5%                                       NS                                          NS                             NS                                                           NS
                                                                                                                                                                                                                                          1.27% A                                                                                                                                                                                                                                                  

  Jäderling^[@bibr34-1178224218823509]^                                               1818                    2189                                                           4.7%                                                         16.3% D\                                                             31.5%                                       25.6%                                       NS                             NS                                                           NS
                                                                                                                                                                                                                                          14.4% A                                                                                                                                                                                                                                                  

  Jäderling^[@bibr35-1178224218823509]^                                               NS                      3063                                                           34.2% Sweden\                                                14.4% Sweden\                                                        18.7% Sweden\                               27.7% Sweden\                               NS                             NS                                                           NS
                                                                                                                                                                             30.8% Australia                                              12.6% Australia                                                      9.9% Australia                              29.4% Australia                                                                                                                         

  Jones^[@bibr11-1178224218823509]^                                                   518                     652                                                            20.3%                                                        10.8%                                                                NS                                                                                      NS                             NS                                                           NS

  Medical Emergency Team End-of-Life Care investigators^[@bibr14-1178224218823509]^   518                     652                                                            Early/late reviews\                                          Early/late reviews\                                                  NS                                          Early/late review\                          NS                             NS                                                           NS
                                                                                                                                                                             16.9%/26.3%                                                  25.4%/35.9%                                                                                                      12.8%/32.3%                                                                                                                             

  Knott^[@bibr17-1178224218823509]^                                                   71                      NS                                                             32%                                                          62%                                                                  NS                                          42%                                         NS                             NS                                                           NS

  O'Horo^[@bibr36-1178224218823509]^                                                  NS                      Retrospective 4408\                                            Retrospective/prospective study\                             Retrospective/prospective study\                                     Retrospective study: 58.6%\                 NS                                          NS                             NS                                                           NS
                                                                                                              Prospective 135                                                13.5%/16.3%                                                  7.2% D /5.9% D                                                       Prospective study: 62.2%                                                                                                                                                            

  Parr^[@bibr37-1178224218823509]^                                                    559                     713                                                            0%                                                           4.8% A                                                               45%                                         6.9% D                                      NS                             NS                                                           NS

  Psirides^[@bibr38-1178224218823509]^                                                313                     351                                                            NS                                                           31.3% (22.5% NFR, 8.8% other LOMT)                                   13.1%                                       2.8% at time of RRT\                        NS                             NS                                                           NS
                                                                                                                                                                                                                                                                                                                                                           19.8% at 30 days                                                                                                                        

  Schneider^[@bibr39-1178224218823509]^                                               458                     557                                                            19.7%                                                        7% D                                                                 11.4%                                       20.1%                                       NS                             NS                                                           NS

  Silva^[@bibr40-1178224218823509]^                                                   389                     389                                                            7.7% B                                                       24.1% D                                                              39.3%                                       18.7% D\                                    NS                             NS                                                           NS
                                                                                                                                                                                                                                                                                                                                                           52.8% overall                                                                                                                           

  Smith^[@bibr41-1178224218823509]^                                                   1117                    NS                                                             11.01% B                                                     5.55% D                                                              17.91%                                      18.8%: deterioration group\                 NS                             NS                                                           NS
                                                                                                                                                                                                                                                                                                                                                           62.64%: cardiac arrest group                                                                                                            

  Smith^[@bibr42-1178224218823509]^                                                   2843                    3860                                                           15.2%                                                        5.7% D                                                               15.5%                                       12.8% early RRT review\                     NS                             NS                                                           NS
                                                                                                                                                                                                                                                                                                                                                           16.7% intermediate RRT review\                                                                                                          
                                                                                                                                                                                                                                                                                                                                                           30.6% for late RRT review\                                                                                                              
                                                                                                                                                                                                                                                                                                                                                           59.4% for patients who had cardiac arrest                                                                                               

  Smith^[@bibr13-1178224218823509]^                                                   NS                      390                                                            11.5%                                                        16.4% A                                                              54%                                         NS                                          NS                             NS                                                           NS

  Stelfox^[@bibr21-1178224218823509]^                                                 5103                    NS                                                             3.8% 4910/5103                                               8.05% D                                                              24.83%                                      32.6%                                       NS                             NS                                                           NS

  Sulistio^[@bibr19-1178224218823509]^                                                351                     456                                                            17.9% NFR\                                                                                                                        21.7%                                       24.5%                                       NS                             NS                                                           15.1%
                                                                                                                                                                             1.42% LOMT                                                                                                                                                                                                                                                                                                            

  Sundararajan^[@bibr43-1178224218823509]^                                            NS                      994                                                            Group 1\                                                     Group 2: Limitations of Medical Treatment at time of RRT review 5%   NS                                          NS                                          NS                             Group 1\                                                     NS
                                                                                                                                                                             LOMT not associated with RRT team review 100%                                                                                                                                                                                                            50% with patient\                                            
                                                                                                                                                                                                                                                                                                                                                                                                                                      90% with next of kin\                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                      Group 2:\                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                      18% with patient\                                            
                                                                                                                                                                                                                                                                                                                                                                                                                                      58% with next of kin                                         

  Tam^[@bibr44-1178224218823509]^                                                     5320                    NS                                                             58%                                                          17% D                                                                8.4% of 'end-of-life' group\                25% of 'end-of-life' group\                 NS                             NS                                                           34% of 'end-of-life' group\
                                                                                                                                                                                                                                                                                                               17% of 'non-end-of-life' group              8% of 'non-end-of-life' group                                                                                                           5.3% of 'non-end-of-life' group

  Tirkkonen^[@bibr45-1178224218823509]^                                               640                     774                                                            0%                                                           9.22%                                                                26% (no LOMT)\                              14% (no LOMT)\                              NS                             76% for new LOMT (7% of total patients)                      NS
                                                                                                                                                                                                                                                                                                               3.4% (LOMT)                                 44% (LOMT)                                                                                                                              

  Tirkkonen^[@bibr46-1178224218823509]^                                               458                     569                                                            6.3%                                                         7.4% D                                                               27.2%                                       26%                                         NS                             NS                                                           NS

  Visser^[@bibr47-1178224218823509]^                                                  132                     141                                                            79.4%                                                        24.2% D                                                              10.6%                                       28%                                         NS                             NS                                                           NS

  White^[@bibr48-1178224218823509]^                                                   800                     1151                                                           22.2%                                                        2% D\                                                                17.2%                                       12.6%                                       NS                             NS                                                           NS
                                                                                                                                                                                                                                          5% A                                                                                                                                                                                                                                                     
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

A, after; B, before; D, During; ICU, intensive care unit; LOMT, limitations of medical treatment; NFR, not for resuscitation; NS, not stated; RRT, Rapid Response Team.

Cancer centre patients.

Included 184 cases where patient died following RRT review; 144 controls who lived.

Hospitals with an RRT (control hospitals without RRT were excluded).

Resuscitation status at admission.

Subset of patients who had a change in NFR status following the RRT review.

Study selection {#section13-1178224218823509}
---------------

The electronic search yielded 312 references and an additional 12 were identified via manual reference searching. A total of 149 duplicate references were excluded, related to studies conducted in the paediatric or mental health setting, or no English language version was available. Potentially relevant titles and abstracts for 175 articles were reviewed. Of these, 124 were excluded as they did not describe an observational or interventional study or did not relate to advance care planning or clinical deterioration requiring the RRT review. A total of 51 were selected for full-text review based on their title and abstract. Studies were excluded that included only one measure of not for resuscitation orders or limitations of medical treatment, with no comparison of how the RRT review impacted the implementation of such orders. Other studies with limited scope such as those that considered only patients who died in hospital or were transferred to an ICU were excluded. A total of 31 articles met the review selection criteria and were included. The study selection process is shown in [Figure 1](#fig1-1178224218823509){ref-type="fig"}.

![Flow diagram of systematic review process.\
RRT, Rapid Response Team.](10.1177_1178224218823509-fig1){#fig1-1178224218823509}

Results {#section14-1178224218823509}
=======

Study characteristics {#section15-1178224218823509}
---------------------

### Study location {#section16-1178224218823509}

Single-site studies were conducted in Australia (14), Brazil (1), Canada (1), Finland (2), New Zealand (1), Saudi Arabia (1), Sweden (1) and the United States (4). Multisite studies were conducted in Australia (2), Canada (2) and New Zealand (1), and three multisite international studies were conducted. Psirides and colleagues^[@bibr38-1178224218823509]^ reported a multicentre study which included 11 hospitals, of which 6 were tertiary and 1 paediatric. Although paediatric RRT reviews were beyond the scope of this review, this study was still included as only 7.1% of the total patients receiving an RRT review call were paediatric, forming only a minor aspect of the data set for this study (A. Psirides, personal communication, 15 July 2017).

### Study design {#section17-1178224218823509}

All studies as listed in [Table 1](#table1-1178224218823509){ref-type="table"} used quantitative methods of data collection. One study used a cluster randomized control study design, one a case-control analysis and all other studies using a retrospective or prospective cohort design. Two studies in this review described quasi-experimental studies.^[@bibr13-1178224218823509],[@bibr29-1178224218823509]^

### Sample characteristics {#section18-1178224218823509}

Studies were conducted at a range of hospital types, including large tertiary hospitals, university-affiliated academic hospitals, community and sub-acute hospitals and one with a specialist cancer-care centre.

The sample sizes ranged from 71 patients receiving an unspecified number of RRT reviews,^[@bibr17-1178224218823509]^ to 5904 reviews carried out with an unspecified number of patients.^[@bibr33-1178224218823509]^ Total patient numbers were 47,850.

Several studies reported a defined patient cohort as part of their overall data collections, including patients at a cancer-care centre,^[@bibr24-1178224218823509]^ or where the RRT review occurred early, compared with late in an admission.^[@bibr14-1178224218823509]^

### Advance care planning characteristics {#section19-1178224218823509}

A summary of the advance care planning characteristics described in the study is included in [Table 2](#table2-1178224218823509){ref-type="table"}. Most studies focussed on reporting the institution of not for resuscitation or limitations of medical treatment orders before, during and after the RRT review. These ranged from 0%^[@bibr37-1178224218823509]^ to 79.4%^[@bibr47-1178224218823509]^ before the RRT review, 1.5%^[@bibr24-1178224218823509]^ to 32.5%^[@bibr29-1178224218823509]^ at the time of the RRT review and 1.27%^[@bibr33-1178224218823509]^ to 62%^[@bibr17-1178224218823509]^ after the RRT review.

The incidence of formal advance care planning documents such as an Advance Directive was reported in only one study,^[@bibr29-1178224218823509]^ with only 5% of patients having a directive in place.

Four studies reported the involvement of a patient, family member or formal Substitute Decision Maker in discussions about limitations of medical treatment or goals of care planning at the time or following a clinical deterioration requiring RRT review. Downar and colleagues^[@bibr32-1178224218823509]^ reported that a family and/or patient conference was held for 16.5% of patients who were for full resuscitation at the time of the RRT review. Sundararajan and colleagues^[@bibr43-1178224218823509]^ found that only 18% of patients were involved in discussions relating to limitations of medical treatment instituted by the RRT, with families or substitute decision makers involved in 58% of cases. This was less than for patients with pre-existing limitations of medical treatment, when patients and their family or substitute decision maker were involved 50% and 90% of the time, respectively. Tirkkonen and colleagues^[@bibr45-1178224218823509]^ reported that families or next of kin were involved in discussions about new limitations of medical treatment (7% of total patients), in 76% of cases.

Palliative care consultation varied greatly among the three articles that reported figures^[@bibr24-1178224218823509],[@bibr32-1178224218823509],[@bibr44-1178224218823509]^ from 1.5% of patients before the clinical deterioration requiring RRT review,^[@bibr24-1178224218823509]^ up to 34% of patients identified as being at the end-of-life after review.^[@bibr44-1178224218823509]^ Escalation of care to a critical care unit ranged from a low of 3.4% of patients following clinical deterioration,^[@bibr45-1178224218823509]^ to a high of 62.2%.^[@bibr36-1178224218823509]^ Downar and colleagues^[@bibr32-1178224218823509]^ reported referral for spiritual care consultation for 12% patients following RRT review; no other studies reported this parameter.

### Mortality {#section20-1178224218823509}

Mortality was reported in most studies as having occurred at the time of the RRT review, at 30 days post-review, for a subgroup of patients, such as those over 60 years, or in hospital. Mortality ranged from 2.8% at the time of the clinical deterioration^[@bibr38-1178224218823509]^ to 62.6% of patients following in-hospital cardiac arrest.^[@bibr39-1178224218823509]^

Discussion {#section21-1178224218823509}
==========

The study setting, research methods, differences in patient cohorts and, not surprisingly, outcomes were highly variable. Most outcomes focussed on the establishment of medical orders relating to end-of-life care, with data on advance care planning discussions establishing patient values, priorities and preferences largely missing. Studies were conducted in a wide variety of countries, where policies relating to end-of-life care and advance care planning differ. In the United States, for example, the Patient Self-Determination Act^[@bibr49-1178224218823509]^ requires all Medicaid and Medicare funded facilities to ask patients about pre-existing advance directives. Australia has no such requirement, although recent national policy developed by the Australian Commission on Safety and Quality in Health Care states that all health professionals should identify existing advance care plans and invite patients to participate in advance care planning.^[@bibr50-1178224218823509]^ The heterogeneity of the methods did not allow the direct comparison of studies or meta-analysis of results.

RRTs have a critical role in hospitals, but approximately one-third of patients reviewed by the RRT are approaching the end-of-life,^[@bibr11-1178224218823509],[@bibr51-1178224218823509]^ such as frail, elderly patients,^[@bibr52-1178224218823509]^ and those with high incidence of co-morbidity.^[@bibr41-1178224218823509],[@bibr42-1178224218823509]^ The aim of this review was to examine the provision of advance care planning in patients who deteriorated in hospital and required RRT review. This builds upon previous reviews conducted by Jones and colleagues^[@bibr15-1178224218823509]^ and Tan and Delaney^[@bibr22-1178224218823509]^ to further understand the role of the RRT with patients approaching the end-of-life.

This review confirmed that a patient's clinical deterioration requiring RRT review led to a focus on end-of-life decision making and establishing ceilings of care by the RRT team, which is entirely appropriate given the role of such teams. However, relying on RRT to service the needs of patients with irreversible and persistent symptomatology is filled with inherent difficulties. These teams have limited knowledge of patients' complex medical history, trajectory of illness and long-term care needs, and a finite window of time in which to appropriately address those needs before further deterioration.^[@bibr19-1178224218823509]^

Goals of care discussions should be separate to RRT review so they are more likely to involve patients and their families in care discussions that consider values, treatment priorities and preferences.^[@bibr43-1178224218823509]^ The primary team is likely to have greater access to the comprehensive medical history, information about current illness, and recent illness trajectory, and it should be their role to guide such conversations. Short timeframes between admission and RRT activation may preclude the provision of advance care planning with the patient, their families and substitute decision maker, and the patient's clinical deterioration itself could be the catalyst to do so.^[@bibr19-1178224218823509]^ Failure to involve patient and their families in care discussions may result in inappropriate activation of the RRT team and the provision of treatments that are not aligned with patient's priorities and preferences.

There may be variability in the quality of end-of-life discussions in acute hospitals following an acute event due to time constraints, skill of staff and a patient's need for urgent care. Some patients may not be ready to consider existential and end-of-life issues; however, they and their family members should be given the opportunity to do so. This may start with providing patients with educational materials and advance care planning forms. Patient and family involvement in advance care planning may lead to greater satisfaction with the end-of-life experience and reduced bereavement risk.^[@bibr7-1178224218823509]^ Few studies in this review included discussion of family member involvement in decision making^[@bibr31-1178224218823509],[@bibr32-1178224218823509],[@bibr45-1178224218823509]^ and further research that considers the provision of advance care planning in the context of clinical deterioration is warranted.

Implications for practice {#section22-1178224218823509}
-------------------------

Advance care planning is an ongoing process, sometimes involving multiple discussions to maximise efficacy, and should be introduced early in a hospital admission to patients at risk of serious deterioration or death. Evidence from the available literature indicated low prevalence of resuscitation orders and formal advance care planning documents, high short- and long-term mortality following clinical deterioration requiring RRT review and a proportion of patients who then require intensive care. Early discussion of goals of care, patient values and preferences as part of an advance care planning process has the potential to reduce the need for RRT intervention and may allow the redistribution of resources to patients whose deterioration is reversible.

Failure to provide care in line with a patient's wishes as they approach may result in unnecessary burden for patients and families, poorer quality of life or increased suffering for patients, and the additional psychological pressures relating to caring for a family member suffering from reduced quality of life.^[@bibr53-1178224218823509]^ Health services may also experience increased burden of care due to unwanted or even futile interventions that have both monetary implications, and psychological implications for staff caring for those patients.^[@bibr54-1178224218823509]^

RRT reviews can be distressing for patients, carers and staff, and may preclude patients from being allowed a natural death. Factors such as effective communication and decision making, respectful and compassionate care, maintenance of self-identity and appropriate surroundings have been identified as important to patients and families.^[@bibr55-1178224218823509]^ In contrast, patients, family members or caregivers may be required to make decisions in a crisis, where patient preferences and priorities for ongoing treatment may be unknown, and responses such as shock, grief, guilt and anxiety may impact clear decision making.^[@bibr56-1178224218823509],[@bibr57-1178224218823509]^

For staff caring for patients at the end-of-life, establishing medical orders such as not for resuscitation or limitations of medical treatment that are clearly identifiable and easily accessed in the context of sudden deterioration are very important. However, they do not replace other aspect of advance care planning.^[@bibr58-1178224218823509]^ Such orders may be less time-intensive and therefore complementary to the RRT.^[@bibr59-1178224218823509]^ This may indicate that patients are afforded decision-making processes that are service-driven at the time of the review out of necessity, rather than patient-driven. Further research is required to define this issue.

Low rates of referral for palliative care management following RRT management may be due to a failure of the studies to capture this or could also be due to the fact that patients died despite all attempts. It may also reveal a lost opportunity to improve end-of-life care through specialist palliative care team management. Evaluation of palliative care referral could be a good outcome measure to assess for as part of patient outcomes measures. Further research examining the role of specialist palliative care services following sudden clinical deterioration is warranted.

Limitations and strengths {#section23-1178224218823509}
-------------------------

From a methodological point of view, this review has several limitations. It is possible some relevant references were not identified. Importantly, the studies were all quantitative and did not consider issues such as quality of life for patients or families. Some studies included small participant numbers and there was a range of hospital settings included, making it difficult to make conclusions about a specific health care setting. Inclusion of studies from a range of countries may influence the interpretation of the results due to policy influences or cultural factors impacting how deterioration, dying and death can be discussed in a clinical setting. Some studies limited their scope to specific disease types or a limited view of the patient journey within the acute care setting. Therefore, meta-analysis of results was not possible. No experimental or qualitative studies were identified, suggesting a gap in the current literature.

This systematic review considered literature published over a wide time frame and included studies that discussed aspects of advance care planning. It has identified several gaps in the literature and highlighted the need to enhance person-centred care to patients at the end-of-life. To our knowledge, it is the first systematic review to examine the provision of advance care planning in the context of sudden clinical deterioration requiring review by an RRT.

Conclusion {#section24-1178224218823509}
==========

To support the growing evidence base, further research is required that seeks to better describe the provision of advance care planning in relation to clinical deterioration in hospital. This includes further research about decision making at the end-of-life, the availability of advance directives, establishment of goals of care, and how patient, families and other substitute decision makers are included in decisions. How RRT review impacts future care, including referral for specialist palliative care, is warranted. This may guide the development of strategies to improve end-of-life care planning, identify those patients who will or will not benefit from aggressive treatment^[@bibr15-1178224218823509]^ and ensure services provided to patients at the end-of-life are timely and appropriate.
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